LIZTOX

Product Overview

LIZTOX is a South Korean prescription botulinum toxin type A injectable medicine manufactured by Huons BioPharma Co., Ltd. Available in LIZTOX 100 Units and LIZTOX 200 Units, the product contains Clostridium botulinum toxin type A formulated with human serum albumin and sodium chloride. Both strengths are supplied as white lyophilized powder in single-use glass vials and require refrigerated storage at 2–8°C.

LIZTOX acts by temporarily inhibiting acetylcholine release at peripheral cholinergic nerve terminals, reducing neuromuscular signaling and the contraction of affected muscles. Its approved South Korean aesthetic indications include the temporary improvement of moderate to severe glabellar lines and lateral canthal lines in eligible adults.

The 100U and 200U formulations provide different quantities of labeled biological potency per vial. Both belong to the same botulinum toxin type A product family, but their use must comply with the applicable product-specific instructions, approved indications, and prescribing regulations.

This TEOSQUARE product page covers LIZTOX 100U and 200U for qualified professional buyers evaluating formulation, vial strength, packaging, manufacturer information, and storage requirements.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A, a neuromodulating protein that temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals.
• 100U and 200U Strengths: Available in two labeled potency presentations, allowing professional buyers to identify the appropriate product strength according to authorized clinical requirements.
• Albumin-Stabilized Formulation: Contains human serum albumin and sodium chloride as pharmaceutical excipients.
• Lyophilized Presentation: Supplied as a white freeze-dried powder in a glass vial, with one vial per manufacturer box.
• South Korean Pharmaceutical Manufacturer: Manufactured by Huons BioPharma Co., Ltd., a South Korean company specializing in botulinum toxin pharmaceutical products.

Composition & Specifications

LIZTOX contains Clostridium botulinum toxin type A as its active pharmaceutical ingredient. Its formulation also includes human serum albumin and sodium chloride.

The active ingredient is expressed in product-specific biological potency units. These units represent measured biological activity and must not be interpreted as protein mass or considered directly interchangeable with units from other botulinum toxin brands.

Botulinum Toxin Type A

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum. Pharmaceutical formulations use controlled quantities of the toxin to temporarily inhibit neurotransmitter release at specific nerve terminals.

Its biological activity is measured using product-specific potency testing. A labeled unit of LIZTOX should not automatically be considered equivalent to one unit of BOTOX, Dysport, Xeomin, or another botulinum toxin product.

Human Serum Albumin

Human serum albumin is included as a pharmaceutical excipient. Albumin is used in certain biological drug formulations to support protein stability during manufacturing, storage, and handling.

Because albumin is derived from human biological material, applicable product-specific safety information and manufacturing controls should be reviewed.

Sodium Chloride

Sodium chloride is included as an excipient contributing to the formulation's physicochemical characteristics.

The presence of sodium chloride and human serum albumin is documented in South Korean pharmaceutical registration information for both LIZTOX 100U and 200U.

Exact excipient quantities should be confirmed against the official prescribing information for each supplied strength. Formulation details must not be inferred solely from the specifications of other botulinum toxin brands.

How LIZTOX Botulinum Toxin Type A Works

LIZTOX contains botulinum toxin type A, which temporarily inhibits the release of acetylcholine at peripheral cholinergic nerve terminals. Acetylcholine is a neurotransmitter responsible for transmitting signals from motor neurons to skeletal muscles.

Inhibition of Neuromuscular Signaling

Under normal physiological conditions, acetylcholine is released from motor nerve terminals and binds to receptors on muscle cells, initiating the electrical events required for muscle contraction.

Botulinum toxin type A interacts with susceptible nerve terminals and disrupts the intracellular machinery responsible for acetylcholine release.

SNAP-25 Cleavage

The enzymatically active light chain of botulinum toxin type A cleaves SNAP-25, a protein involved in the SNARE complex responsible for neurotransmitter vesicle fusion.

Disruption of this process reduces acetylcholine release and temporarily inhibits neuromuscular transmission.

Temporary Muscle Relaxation

Reduced neuromuscular signaling causes temporary relaxation of affected skeletal muscles. This mechanism provides the pharmacological basis for approved aesthetic applications involving muscle-related facial wrinkles.

Neuromuscular function gradually recovers over time. The onset, intensity, and duration of clinical effects depend on the product formulation, approved indication, administration conditions, and individual patient characteristics.

The mechanism described above is established for botulinum toxin type A. It does not establish identical clinical performance or interchangeable dosing between LIZTOX and other botulinum toxin preparations.

Available LIZTOX Variants

LIZTOX 100 Units and LIZTOX 200 Units are separately registered prescription formulations in South Korea. Both contain Clostridium botulinum toxin type A and share the same general pharmaceutical formulation category.

The principal distinction between these two presentations is their labeled biological potency per vial.

LIZTOX 100 Units

LIZTOX 100U is a South Korean prescription injectable medicine containing 100 units of Clostridium botulinum toxin type A per vial.

The formulation is supplied as a white lyophilized powder in a colorless glass vial. Human serum albumin and sodium chloride are included as excipients.

LIZTOX 100U was first authorized in South Korea on October 10, 2016. Its registered aesthetic indications include temporary improvement of moderate to severe glabellar lines and lateral canthal lines in eligible adults.

Its product strength, labeling, and approved indications should be checked against the currently applicable prescribing information.

LIZTOX 200 Units

LIZTOX 200U contains 200 units of Clostridium botulinum toxin type A per vial and is manufactured by Huons BioPharma.

Like the 100-unit presentation, LIZTOX 200U is supplied as a lyophilized formulation containing human serum albumin and sodium chloride.

The 200-unit formulation received its initial South Korean authorization on July 9, 2021. Its registered indications include selected aesthetic applications involving facial expression lines, with additional therapeutic indications subject to the currently approved product labeling.

The higher vial strength refers to twice the labeled total biological potency of the 100-unit product. It does not imply greater clinical activity per unit, superior efficacy, or a different botulinum toxin serotype.

This comparison includes only LIZTOX 100U and 200U. Other registered strengths are not part of this TEOSQUARE product group. Approved indications may differ by strength and change following regulatory updates.

Approved Indications & Regulatory Information

LIZTOX is registered in South Korea as a prescription pharmaceutical product containing Clostridium botulinum toxin type A.

The manufacturer's published Korean prescribing information identifies the following aesthetic indications for the relevant formulations:

• Glabellar Lines: Temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65 years.
• Lateral Canthal Lines: Temporary improvement of moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity in eligible adults aged 19–65 years.

The Korean registrations also include therapeutic indications for certain formulations. These indications are subject to product strength, authorization history, and the applicable prescribing information.

Regulatory approval in South Korea does not establish equivalent authorization in the United States, European Union, or other countries. The approved indications, prescribing requirements, and legal distribution conditions must be verified independently for each destination market.

The indications summarized above reflect South Korean product information. This description does not establish approval for other aesthetic applications, anatomical areas, or off-label procedures.

Packaging & Product Presentation

LIZTOX 100U and 200U are supplied as freeze-dried pharmaceutical formulations in individual glass vials. Each manufacturer box contains one vial of the corresponding labeled strength.

The labeled potency describes the biological activity of the dried product contained in each vial. It does not represent a liquid volume or a recommended administration quantity.

The original manufacturer packaging should be inspected to confirm the product name, strength, lot number, expiration date, and applicable regulatory labeling.

LIZTOX is a prescription biological medicine. Its preparation and administration must follow the official prescribing information and be performed only by appropriately authorized healthcare professionals.

Storage & Handling

Huons BioPharma specifies refrigerated storage at 2°C to 8°C for both LIZTOX 100U and 200U. The products should be maintained in tightly closed containers under the conditions stated in their official labeling.

• Storage Temperature: Refrigerate at 2°C to 8°C.
• Container: Keep the original vial tightly closed and maintain packaging integrity.
• Temperature Control: Maintain the manufacturer-specified refrigerated conditions during storage and handling.
• Product Integrity: Do not use a product if the original vial or its packaging has been compromised.
• Product Traceability: Verify the labeled potency, batch number, expiration date, manufacturer, and applicable documentation.

Requirements for a prepared solution are distinct from those for an unopened lyophilized vial. Any preparation, use, or disposal must comply with the official product-specific prescribing information.

Refrigerated storage requirements are verified for both strengths. Do not assume that storage conditions or allowable handling periods are interchangeable with those of other botulinum toxin products.

Safety & Professional Use

LIZTOX contains a biologically active neurotoxin and is classified as a prescription medicine in South Korea. Its use requires appropriate medical supervision, patient assessment, and compliance with the official prescribing information.

Potential adverse reactions associated with botulinum toxin type A products include injection-site discomfort, swelling, bruising, headache, and unintended weakness of adjacent muscles.

Serious adverse reactions may include excessive muscle weakness, swallowing difficulties, breathing problems, and symptoms associated with the spread of toxin effects beyond the intended administration area.

Patients with known hypersensitivity to botulinum toxin type A or formulation components, or infection at a proposed administration site, may have contraindications to treatment. Certain neuromuscular disorders and concomitant medications may require additional precautions.

Because LIZTOX contains human serum albumin, its biological origin and applicable product-specific safety information should also be considered.

LIZTOX potency units are specific to the product's biological assay system. Units must not be directly converted into equivalent quantities of other botulinum toxin brands.

Professional buyers must verify the regulatory authorization, permitted indications, prescribing restrictions, and lawful distribution conditions in the destination country.

This description is intended for professional product identification and comparison. It does not replace the official prescribing information, provide administration instructions, or establish individual patient suitability.

Frequently Asked Questions